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ABSTRACT Posttranscriptional regulation of HIV-1 replication is finely controlled by
viral and host factors. Among the former, Rev controls the export of partially spliced
and unspliced viral RNAs from the nucleus and their translation in the cytoplasm or
incorporation into new virions as genomic viral RNA. To investigate the functional
role of the Rev cofactor MATR3 in the context of HIV infection, we modulated its ex-
pression in Jurkat cells and primary peripheral blood lymphocytes (PBLs). We con-
firmed that MATR3 is a positive regulator of HIV-1 acting at a posttranscriptional
level. By applying the same approach to J-lat cells, a well-established model for the
study of HIV-1 latency, we observed that MATR3 depletion did not affect transcrip-
tional reactivation of the integrated provirus, but caused a reduction of Gag produc-
tion. Following these observations, we hypothesized that MATR3 could be involved
in the establishment of HIV-1 posttranscriptional latency. Indeed, mechanisms acting
at the posttranscriptional level have been greatly overlooked in favor of transcrip-
tional pathways. MATR3 was almost undetectable in resting PBLs, but could be
promptly upregulated upon cellular stimulation with PHA. However, HIV latency-
reversing agents were poor inducers of MATR3 levels, providing a rationale for their
inability to fully reactivate the virus. These data have been confirmed ex vivo in cells
derived from patients under suppressive ART. Finally, in the context of MATR3-
depleted J-lat cells, impaired reactivation by SAHA could be fully rescued by MATR3
reconstitution, demonstrating a direct role of MATR3 in the posttranscriptional regu-
lation of HIV-1 latency.
IMPORTANCE The life cycle of HIV-1 requires integration of a DNA copy into the ge-
nome of the host cell. Transcription of the viral genes generates RNAs that are ex-
ported to the cytoplasm with the contribution of viral and cellular factors to get
translated or incorporated in the newly synthesized virions. It has been observed
that highly effective antiretroviral therapy, which is able to reduce circulating virus
to undetectable levels, cannot fully eradicate the virus from cellular reservoirs that
harbor a transcriptionally latent provirus. Thus, persistence of latently infected cells
is the major barrier to a cure for HIV-1 infection. In order to purge these reservoirs
of latently infected cells, it has been proposed to activate transcription to stimulate
the virus to complete its life cycle. This strategy is believed to unmask these reser-
voirs, making them vulnerable to the immune system. However, limited successes of
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this approach may indicate additional posttranscriptional restrictions that need to be
overcome for full virus reactivation. In this work we identify the cellular protein
MATR3 as an essential cofactor of viral RNA processing. Reactivation of HIV-1 tran-
scription per se is not sufficient to allow completion of a full life cycle of the virus if
MATR3 is depleted. Furthermore, MATR3 is poorly expressed in quiescent CD4 T
lymphocytes that are the major reservoir of latent HIV-1. Cells derived from aviremic
HIV-1 patients under antiretroviral therapy didn’t express MATR3, and most impor-
tantly, latency-reversing agents proposed for the rescue of latent provirus were inef-
fective for MATR3 upregulation. To conclude, our work identifies a cellular factor re-
quired for full HIV-1 reactivation and points to the revision of the current strategies
for purging viral reservoirs that focus only on transcription.
KEYWORDS HIV-1, latency, posttranscription, MATR3, RNA, latency-reverting agents,
LRA, shock and kill, reservoir, RNA binding proteins, human immunodeficiency virus,
posttranscriptional control mechanisms
Combination antiretroviral therapy (cART) has successfully reduced human immu-nodeficiency virus type 1 (HIV-1)-related disease (1). However, effective therapy
requires a lifelong regimen of cART to maintain undetectable viremia. Blood and tissue
reservoirs that are insensitive to drug treatment maintain a source of virus, which
inevitably rebounds following interruption of therapy. The most studied reservoirs are
quiescent memory T cells that harbor an integrated transcriptionally silent but
replication-competent cDNA copy of the virus in their genomes. Experimental virus
eradication therapies called “shock and kill” strategies are being proposed to awake
dormant viruses in the latent reservoir. Virus-producing cells would then be susceptible
to HIV-induced killing and clearance by the immune system (2, 3). Current regimens for
HIV reactivation are based on drugs known as latency-reversing agents (LRAs) that
induce transcriptional activation of the provirus (1, 4). Despite successes ex vivo, clinical
studies of single LRAs have achieved only limited success in the depletion of the
reservoir (5, 6). Failure to completely eradicate viral infection with LRAs in vivo might be
related to poor immunity toward reactivated cells, and studies are under way using
combination of LRAs associated with strategies to improve the HIV-specific immune
response (7). Alternatively, some cells of the reservoir could maintain a latent
replication-competent provirus insensitive to LRA either because of insufficient pen-
etrance of the drug or because some posttranscriptional block remains insensitive to
LRAs. Despite few reports, the latter aspect has been greatly overlooked and may
severely impact successful LRA approaches (8).
HIV transcription is extremely efficient once the viral Tat transactivator is expressed,
generating a positive feedback loop (9, 10). Nascent viral RNA is then processed by the
cellular machinery to generate a number of spliced, partially spliced, or unspliced
(genomic) products. While fully spliced viral RNAs follow the classical nuclear export
pathway, partially spliced and unspliced viral RNAs follow an alternative route mediated
by the viral protein Rev (11). Rev binds the Rev-responsive element (RRE) and promotes
the export of RRE-containing viral RNAs from the nucleus through interaction with
Exportin 1 (XPO1) (12–14). We previously affinity purified the HIV ribonucleoprotein
complex in the cell nucleus (15). One of the proteins identified by mass spectrometry
was the matrix-associated RNA binding protein Matrin 3 (MATR3), which was shown to
interact with Rev through RRE and was required for Rev-mediated export of RRE-
containing HIV-1 RNAs (15, 16). MATR3 forms a complex with another protein identified
in the screen: the polypyrimidine tract-binding protein-associated binding factor PSF
(splicing factor proline and glutamine rich, SFPQ), which was already implicated in
Rev-mediated export of HIV-1 RNAs (17). We could demonstrate that, while Rev and PSF
bind the viral pre-mRNA at the site of viral transcription, MATR3 interacts at a subse-
quent step involved in nuclear export. Therefore, PSF and MATR3 define a nuclear
pathway for RRE-containing HIV-1 RNAs that is hijacked by the viral Rev protein (18).
In this work we provide evidence of a critical role for MATR3 in acute HIV-1 infection
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and reactivation from latency. Data from CD8 depleted peripheral blood mononuclear
cells (PBMC) from aviremic cART patients indicate an intriguing correlation between
low levels of MATR3/PSF and poor performance of LRAs ex vivo. We believe these data
will stimulate research toward the definition of posttranscriptional pathways in the
reactivation from latency and their exploitation for new-generation LRAs.
RESULTS
MATR3 depletion inhibits nuclear export of HIV-1 unspliced RNA in lympho-
cytes. To investigate the role of MATR3 in HIV-1 replication, we needed a stable
depletion of MATR3 in CD4 T lymphocytes. To this end we identified two potent
shRNAs targeting MATR3, shMATR3_905 and shMATR3_906 (Fig. 1A). Depletion of
MATR3 was previously shown to affect Gag expression and the Rev-mediated nuclear
export of unspliced viral RNA (15, 18). Consistently, infection of Jurkat cells depleted of
MATR3 (Fig. 1B) with HIV-1 NL4.3 results in reduced intracellular expression of Gag as
shown in Fig. 1C, corresponding to a marked decrease of extracellular p24 (Fig. 1D). To
rule out a transcriptional effect of MATR3 depletion, Jurkat cells were infected with
equal amounts of VSV-G pseudotyped, firefly luciferase-expressing HIV-1 (NL-4.3-R-E-
luc) capable of a single cycle of infection. The luciferase reporter that is placed in the
nef gene is expressed from a spliced transcript driven by the 5= LTR. As shown in Fig. 1E,
luciferase activity was not affected by shMATR3 depletion. To pinpoint the step at
which HIV-1 replication was affected, we measured transcript levels in the nucleus and
cytoplasm of infected cells depleted of MATR3. To check for the quality of nuclear and
cytoplasmic fractionation and shRNA-mediated knockdown of MATR3, a routine immu-
noblot was performed for Hsp90 and PARP, which are the controls for cytoplasmic and
nuclear fractions, respectively. Coomassie blue-stained SDS-PAGE was used as loading
control (Fig. 1F). MATR3 could be recovered only from the nuclear fraction, as previ-
ously observed, and was greatly depleted by shRNA treatment. qRT-PCR was performed
to analyze HIV unspliced RNA levels. We found that the levels of unspliced mRNA
slightly increased in the nuclear fraction, but decreased significantly in the cytoplasmic
fraction of MATR3-depleted cells (Fig. 1G). These results, obtained in the context of
acute infection of CD4 T lymphocytes with a replication-competent virus, further
strengthen and extend our previous observation that MATR3 selectively acts on the
Rev-dependent nuclear export of unspliced viral RNA.
MATR3 depletion inhibits HIV-1 replication in lymphocytes. We then proceeded
to examine the replication kinetics of HIV-1 when MATR3 is depleted. At 24 hours after
transduction with shRNAs, Jurkat cells were cultured in RPMI containing puromycin for
72 h and then left without selection. Immunoblotting showed a high level of depletion
maintained for more than 2 weeks (Fig. 2A), and viability assays showed lack of
cytotoxicity (not shown). Infection with HIV-1 NL4.3 resulted in the release of virions
from day 2 in shCTRL cells, while a robust increase of p24 could not be detected in
shMATR3 cells up to 14 days postinfection (Fig. 2B).
To extend this observation, primary peripheral blood lymphocytes (PBLs) from
healthy donors were activated with PHA/IL-2, transduced with shRNA, and infected with
HIV-1 as described above. Figure 2C and D show the efficient depletion of MATR3, the
corresponding decrease of intracellular Gag, and the inhibition of HIV-1 NL4.3 replica-
tion.
These results demonstrate that depletion of MATR3 affects acute HIV-1 infection of
CD4 T lymphocytes.
Ectopic MATR3 increases viral replication in lymphocytes. Jurkat cells were
transduced with a lentiviral vector expressing flag-tagged MATR3, which resulted in
higher MATR3 protein levels (Fig. 3A). Infection of these cells with HIV-1 NL4.3 showed
an increased intracellular expression of Gag (Fig. 3B). Nucleocytoplasmic fractionation
of infected Jurkat cells overexpressing f-MATR3 (Fig. 3C) resulted in a major decrease of
US HIV-1 RNA in the nuclear fraction (Fig. 3D), while MS RNAs were not affected
(Fig. 3E). Decrease of US RNA in the nucleus is compatible with increased export
mediated by MATR3, while steady-state invariant US RNA levels in the cytoplasm could
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FIG 1 Depletion of MATR3 inhibits HIV-1 Gag expression and nuclear export of unspliced RNA. (A)
Optimization of shMATR3 lentivectors. HeLa cells were transduced with lentivectors targeting MATR3
(shMATR3) or with control shRNA (shCTRL). Three days after puromycin selection, MATR3-depleted cells
were harvested for immunoblotting. -Tubulin is the protein loading control. (B) Depletion of MATR3 in
Jurkat cells. Lentivectors for MATR3 depletion were used to transduce Jurkat cells, which were processed
as indicated above. -Actin is the loading control. (C) MATR3 knockdown leads to the decrease of HIV-1 Gag
expression. Jurkat cells were transduced with shMATR3. Three days after puromycin selection, MATR3-
depleted cells were infected with replication-competent HIV-1 NL4.3 virus and harvested 48 h postinfection
for immunoblotting. -Actin is the protein loading control. (D) MATR3 depletion leads to the decrease in
the extracellular release of HIV-1 p24. MATR3-depleted Jurkat cells generated as described above were
infected with HIV-1 pNL-4.3 virus, and supernatant was harvested 48 h postinfection. Virion production in
the supernatant was quantified by HIV-1 p24 ELISA. Average values of three independent experiments are
shown, with standard deviations (SD) and P values as described in Materials and Methods. (E) HIV-1
LTR-driven transcription is not affected by MATR3 knockdown. MATR3-depleted Jurkat cells generated as
described above were infected with HIV-1 pNL-4.3 luciferase virus (pNL-4.3-R-E-luc) pseudotyped with the
VSV-G envelope. Luciferase was measured 48 h postinfection. Relative luciferase expression was normalized
to total protein levels as measured by Bradford assay. The results of three independent experiments are
shown as mean values  SD. (F) Nucleocytoplasmic fractionation of Jurkat cells. Following shMATR3
transduction and infection as described above, Jurkat cells were subjected to nucleocytoplasmic fraction-
ation. The cytoplasmic marker protein Hsp90 was detected only in the cytoplasm, while the nuclear marker
PARP was detected only in the nuclear fraction. MATR3 was detected only in the nucleus of shCTRL-treated
cells and depleted from the nuclear extracts of cells treated with shMATR3_905 and shMATR3_906. The
(Continued on next page)
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be explained by increased release of HIV particles (Fig. 3B). However, we cannot exclude
MATR3-dependent effects on the stability of HIV US RNA mediated by the zinc finger
antiviral protein (ZAP) complex as proposed by Erazo and Goff (19).
To confirm a positive effect of f-MATR3 overexpression on HIV-1 replication, PBLs
from healthy donors were transduced with the lentiviral vector expressing f-MATR3 and
infected with HIV-1 NL4.3. As shown in Fig. 3F, transduction of f-MATR3 significantly
increased MATR3 levels, which resulted in higher levels of viral particles released by the
infected PBLs (Fig. 3G). These data complement the depletion data described above
and confirm the role of MATR3 as a posttranscriptional regulator of HIV-1 RNA and viral
replication.
MATR3 depletion inhibits reactivation from latency. In order to investigate the
role of MATR3 in reactivation from HIV-1 latency, we took advantage of the J-lat 8.4
FIG 1 Legend (Continued)
Coomassie blue-stained gel was used as the loading control. (G) HIV-1 unspliced RNA levels are modulated
by MATR3. Quantitative analysis of unspliced HIV-1 RNA levels in Jurkat cells treated as above. Unspliced
(US) RNA levels were analyzed by quantitative real-time PCR on nuclear (NF) and cytoplasmic (CF) fractions.
Data were normalized to GAPDH mRNA expression and presented as fold changes compared to shCTRL.
Average values of triplicate independent experiments are shown, with standard deviations (SD) and P
values as described in Materials and Methods.
FIG 2 MATR3 depletion inhibits HIV-1 replication. (A) Long-term depletion of MATR3 in Jurkat cells.
Western blot analysis of MATR3 after transduction at different time points. -Actin is the protein loading
control. (B) Impaired HIV-1 replication in MATR3-depleted Jurkat cells. Jurkat cells depleted for MATR3 as
described were infected with replication-competent HIV-1 pNL-4.3 virus, and supernatant was harvested
after every 2 days to monitor HIV replication. Virion production in the supernatant was quantified by
HIV-1 p24 ELISA (shCTRL cells are shown only until peak p24, then the signal decreased due to cytotoxic
effects of infection). The results of two independent experiments are shown as mean values  SD. (C)
MATR3 knockdown in peripheral blood lymphocytes. Primary human peripheral blood lymphocytes
(PBLs) were transduced with shMATR3. Four days posttransduction, MATR3-depleted cells were har-
vested for immunoblotting against MATR3 or Gag as indicated. -Actin is the protein loading control. (D)
MATR3 depletion inhibits HIV-1 replication in primary human peripheral blood lymphocytes. MATR3-
depleted PBLs, generated as described above, were infected with replication-competent HIV-1 pNL-4.3
virus. The supernatant was harvested every 2 days to monitor HIV replication. Virion production in the
supernatant was quantified by HIV-1 p24 ELISA. The results of two independent experiments from
different donors are shown as mean values  SD.
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HIV-1 latency model (20). Cells were transduced with shMATR3 to obtain a prolonged
silencing of MATR3 (Fig. 4A) and then reactivated with TNF- to induce HIV-1 tran-
scription. As shown in Fig. 4B, cell-associated Gag protein levels were markedly reduced
upon MATR3 depletion. Consistently, p24 levels in the medium were also reduced
(Fig. 4C), while HIV-1 transcription, which is measured by the GFP reporter from a
FIG 3 Ectopic MATR3 promotes HIV-1 replication. (A) Overexpression of MATR3 in Jurkat cells. Flag-
tagged MATR3 (f-MATR3) was overexpressed in Jurkat cells following transduction with a lentivector.
Immunoblot with the indicated antibodies was performed following blasticidin selection. -Actin is the
protein loading control. (B) Overexpression of MATR3 leads to an increase of Gag expression. Jurkat cells
were transduced with f-MATR3 or with a control lentivector. Five days after blasticidin selection, cells
were infected with replication-competent HIV-1 pNL-4.3 virus and harvested 48 h postinfection for
immunoblotting. -Actin is the protein loading control. (C) MATR3 RNA is increased both in the nucleus
(NF) and in the cytoplasm (CF). Nucleocytoplasmic fractionation of Jurkat cells was performed as
described in Materials and Methods. Quantification of MATR3 mRNA normalized to GAPDH expression is
presented as fold changes compared to mock-transduced cells. Average values of duplicate independent
experiments are shown, with standard deviations (SD) and P values as described in Materials and
Methods. (D) HIV-1 unspliced RNAs decrease in the nucleus when MATR3 is overexpressed. Quantitative
analysis of RNA levels was performed as described above. (E) HIV-1 multiply spliced RNAs are not affected
when MATR3 is overexpressed. Quantitative analysis of RNA levels was performed as described above. (F)
Ectopic f-MATR3 expression in PBLs. Lentivectors for the expression of f-MATR3 were used to transduce
PBLs. Cells were then lysed and blotted for MATR3 and -actin as loading control. (G) Ectopic f-MATR3
expression enhances HIV-1 replication in PBLs. PBLs expressing f-MATR3 were infected with replication-
competent HIV-1 NL4.3 virus. The supernatant was harvested every 2 days to monitor HIV replication.
Virion production in the supernatant was quantified by HIV-1 p24 ELISA. The results of two independent
experiments are shown as mean values  SD.
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spliced HIV-1 mRNA, was not affected by MATR3 depletion (Fig. 4D). These experiments
show that depletion of MATR3 resulted in a reduced ability of TNF- to reactivate HIV
from latency. TNF- is a potent and unspecific inducer of HIV-1 reactivation, and the
small, albeit significant, reduction of p24 release in conditions of MATR3 depletion
FIG 4 MATR3 depletion impairs full reactivation of HIV-1 from latency. (A) Efficiency of MATR3 depletion in
J-lat 8.4 cells. MATR3 depletion was obtained with shMATR3 as described above (Fig. 1A). Three days after
puromycin selection, MATR3-depleted cells were harvested for immunoblotting. -Actin is the protein loading
control. (B) MATR3 depletion leads to reduced HIV-1 Gag expression. J-lat 8.4 cells were transduced with
shMATR3. Three days after puromycin selection, MATR3-depleted cells were stimulated with TNF- (30 ng/ml),
and 48 h postinduction, samples were collected for immunoblotting. -Actin is the protein loading control.
(C) MATR3 depletion leads to the decrease in the extracellular release of HIV-1 Gag. MATR3-depleted J-lat cells
generated as described above were stimulated with TNF-, and supernatant was harvested 48 h postinfec-
tion. Virion production in the supernatant was quantified by HIV-1 p24 ELISA. Results from three separate
experiments are shown as mean values  SD. (D) HIV-1 LTR-driven transcription is not affected by MATR3
knockdown. MATR3-depleted J-lat 8.4 cells treated as described above were analyzed for GFP expression by
cytofluorimetry. The results of three independent experiments are shown as mean values  SD. (E) Expression
of MATR3 and other cofactors in PBLs. Freshly isolated lymphocytes from peripheral blood from buffy coat
were stimulated with PHA/IL-2 for 3 days. Cell lysates were blotted with the indicated antibodies. Loading
control is the blotting membrane stained with Ponceau S. (F) Expression of MATR3 in primary CD4 T
lymphocytes. Primary CD4 T cells were purified by positive selection with magnetic beads and stimulated
with PHA/IL-2. Three and 6 days postinduction, cell lysates were blotted with the indicated antibodies using
both -tubulin and vimentin as loading controls.
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indicates that MATR3 is involved in posttranscriptional control of HIV-1 latency, but may
not be the only factor involved.
One intriguing hypothesis is that certain host cellular factors, which are essential for
HIV-1 gene expression, might be limited, and/or their activities might be perturbed, in
latently infected cells. Therefore, we explored the expression levels of MATR3 and other
cofactors of HIV-1 transcription, such as cyclin T1, or acting posttranscriptionally (PSF
and the polypyrimidine tract binding protein PTB) in primary PBLs. We observed that
these factors were detectable at very low levels in quiescent PBLs, but were highly
induced by PHA (Fig. 4E). The same was observed for purified primary CD4 T cells
(Fig. 4F). PBLs are heterogeneous and a small proportion of cells may be activated and
therefore responsible for the low basal levels of MATR3 observed. More restricted
populations such as CD3 or CD3/CD4 T cells showed activation markers HLADR and
CD69 in an average of 5.7%  1.6% and 4.9%  1.2% of cells, respectively. Hence, levels
of MATR3 and other transcriptional and posttranscriptional cofactors required for full
reactivation of HIV-1 are low in quiescent lymphocytes, possibly contributing to HIV-1
latency.
Modulation of MATR3 levels in HIV-1-infected patients’ PBLs following treat-
ment with latency-reversing agents. Several latency-reversing agents have been
proposed in strategies for HIV-1 eradication (1). Vorinostat (SAHA) is a well-described
histone deacetylase inhibitor capable of inducing high levels of HIV-1 transcription. We
observed that uninfected PBLs treated with SAHA did not show a significant increase
of MATR3 protein levels, as opposed to PHA activation (Fig. 5A). To confirm this
observation, we established a protocol of HIV reactivation from patients’ cells. Ex vivo
cell cultures of CD8-depleted PBMCs from 7 HIV patients on cART were treated with
0.5 M SAHA, corresponding to the concentration found in plasma (21), or with
anti-CD3 and anti-CD28 antibodies that serve as positive control of global T cell
activation. We assessed the levels of MATR3 mRNA (Fig. 5B), PSF mRNA (Fig. 5C),
cell-associated unspliced HIV-1 RNA (CA-US HIV-1 RNA, Fig. 5D), and extracellular HIV-1
RNA (EC HIV-1 RNA, Fig. 5E) at days 3 and 6 of treatment/stimulation. MATR3 and PSF
mRNA levels did not increase upon SAHA treatment, in contrast to the increases
observed in TCR-stimulated cells (Fig. 5B and C). We observed that in cells following
SAHA treatment, levels of CA-US HIV-1 RNA increased at day 6 and reached similar
levels of increase as observed in the positive control (Fig. 5D). Importantly, levels of
genomic extracellular HIV-1 RNA were not increased following SAHA treatment and
were similar to levels observed in mock cells (Fig. 5E). These results suggest that SAHA
induces HIV transcription but does not lead to similar effects at the level of HIV-1
production as assessed by measurement of extracellular HIV-1 RNA levels. These data
are consistent with a scenario where inability of SAHA to increase the levels of MATR3
and PSF mRNA could be linked with its inability to fully reactivate HIV-1.
In addition to SAHA, we tested several LRAs with different modes of action at
concentrations found in plasma: the putative PTEN inhibitor disulfiram, the deacetylase
inhibitor romidepsin, and the PKC agonist IngenolB in combination with the BET
inhibitor JQ1. Protein levels of MATR3 did not increase compared to mock treatment,
with the exception of romidepsin, which showed a strong decrease (Fig. 6A). However,
we observed that at the concentration of romidepsin used in this experiment there is
a consistent cytotoxic effect leading to a generalized decrease of protein levels, as
evident looking at the vimentin loading control. To conclude this set of experiments,
treatment of HIV-1-infected cells from three patients with these drugs didn’t show any
significant change of MATR3 mRNA levels, which is consistent with our hypothesis
(Fig. 6B).
Results above showed that LRAs did not upregulate MATR3 in quiescent T cells, and
we propose that this could be related to their inability to fully reactivate HIV-1 from
latency. To establish a direct link between MATR3 depletion and reactivation from
latency, we returned to the J-lat model of HIV-1 latency. Endogenous MATR3 is highly
expressed in this model of latency, which could be depleted by shMATR3 treatment. As
shown in Fig. 7C, SAHA induced p24 release in J-lat cells, while shMATR3 treatment
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FIG 5 MATR3 levels in cART-treated aviremic patients’ cells correlate with low efficiency of full virus reactivation by SAHA.
(A) MATR3 protein levels remain low in PBLs treated with SAHA. Uninfected PBLs were treated with 0.5 M SAHA or
5 g/ml PHA for three or 6 days. Whole-cell extracts were blotted for MATR3 and vimentin as loading control. Quantifi-
cation was performed on independent blots from 4 different donors acquired with ImageJ and normalized to vimentin. (B)
MATR3 mRNA remains low in ex vivo cultures of CD8-depleted PBMCs from cART-treated HIV aviremic patients treated
with SAHA. Latently infected, CD8-depleted PBMCs purified from blood of 7 cART-treated HIV aviremic patients were
activated with anti-CD3 and anti-CD28 antibodies (C) or 0.5 M SAHA for the indicated time points. MATR3 mRNA levels
were quantified by RT-qPCR and reported as fold change compared to mock treatments per time point, normalized to the
changes in total cellular RNA (dotted line). Data sets were analyzed using one-sample Wilcoxon tests to compare the
normalized values in SAHA and CD3/CD28 columns to 1. P  0.05 was considered statistically significant. SAHA day 3 versus
mock day 3, P  0.2969; CD3CD28 day 3 versus mock day 3, P  0.0313; SAHA day 6 versus mock day 6, P  0.4688;
CD3CD28 day 6 versus mock day 6, P  0.0156. (C) PSF mRNA remains low in ex vivo cultures of CD8-depleted PBMCs
from cART-treated HIV aviremic patients treated with SAHA. Same as in panel B above. SAHA day 3 versus mock day 3,
P  0.0343; CD3CD28 day 3 versus mock day 3, P  0.0313; SAHA day 6 versus mock day 6, P  0.5781; CD3CD28 day
6 versus mock day 6, P  0.0156. (D) Treatment with SAHA efficiently induces HIV-1 transcription. Cell-associated unspliced
HIV-1 RNA (CA-US HIV-1 RNA) extracted from ex vivo cultures as in panel B was quantified by RT-qPCR and expressed as
HIV RNA copy numbers/g of total cellular RNA. Open symbols indicate undetectable samples and report an estimated
value calculated as 50% of a detection limit per sample. The detection limit depended on the amounts of cellular RNA and
therefore differed between samples. The medians are represented. Data sets were analyzed using a paired, nonparametric
Wilcoxon test. P  0.05 was considered statistically significant. SAHA day 3 versus mock day 3, P  0.1875; CD3CD28 day
3 versus mock day 3, P  0.3125; SAHA day 6 versus mock day 6, P  0.2188; CD3CD28 day 6 versus mock day 6,
P  0.2969. (E) Treatment with SAHA does not induce HIV-1 particle release. Extracellular genomic viral RNA (EC HIV-1 RNA)
(Continued on next page)
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completely abolished the effect of the drug on particle release. This defect was
efficiently rescued by ectopic expression of a MATR3 variant engineered to be resistant
to shRNA activity in both J-lat 6.3 and J-lat 8.4 clones (Fig. 7). By this approach we could
mimic a MATR3-limiting cellular environment and address the question of its role in the
posttranscriptional regulation in the context of SAHA induction. This experiment
FIG 5 Legend (Continued)
from patients’ cells treated as in panel B was quantified using RT-qPCR and reported as HIV RNA copy numbers/ml of
plasma. Symbols and statistics as reported for panel D above. SAHA day 3 versus mock day 3, P  0.6875; CD3CD28 day
3 versus mock day 3, P  0.1563; SAHA day 6 versus mock day 6, P  0.2969; CD3CD28 day 6 versus mock day 6,
P  0.0313.
FIG 6 MATR3 levels in cART-treated aviremic patients’ cells correlate with low efficiency of full virus reactivation by
LRAs. (A) Treatment with LRAs did not change MATR3 protein levels. Healthy donors’ uninfected PBLs treated as
described in Fig. 5B were stimulated for three or 6 days with 5 g/ml PHA, 0.5 M SAHA, 0.5 M disulfiram, or 0.0175
M romidepsin or with a combined treatment of 10 nM IngenolB with 0.5 M JQ1. Whole-cell extracts were blotted
for MATR3 and vimentin as loading control. Quantification was performed on independent blots from 3 different
donors acquired with ImageJ and normalized to vimentin. (B) Treatment with LRAs did not change MATR3 mRNA
levels. Ex vivo cell cultures as in Fig. 5B were treated with LRAs as indicated above for Fig. 5E. MATR3 mRNA levels
were quantified by RT-qPCR and reported as fold change compared to mock treatments per time point, normalized
to the changes in total cellular RNA (dotted line). Data from the 3 patients were analyzed using the one-sample
Student t test with significance at P  0.05. SAHA day 3 versus mock day 3, P  0.1917; disulfiram day 3 versus mock
day 3, P  0.351; romidepsin day 3 versus mock day 3, P  0.1909; IngenolB  JQ1 day 3 versus mock day 3,
P  0.8525; CD3CD28 day 3 versus mock day 3, 0.3819; SAHA day 6 versus mock day 6, 0.6606; disulfiram day 6
versus mock day 6, P  5874; romidepsin day 6 versus mock day 6, P  0.2681; IngenolB  JQ1 day 6 versus mock
day 6, P  0.7147; CD3CD28 day 6 versus mock day 6, P  0.0237.
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provides a direct evidence of the role of MATR3 in the posttranscriptional regulation of
HIV-1 latency.
DISCUSSION
MATR3 is an RNA-binding component of the nuclear matrix involved in diverse
processes, including the response to DNA damage (22), mRNA stability (23), RNA
splicing (24), and nuclear retention of hyperedited RNA (25). Mutations in MATR3 have
also been linked to familial amyotrophic lateral sclerosis, adding to a list of mutations
in many proteins that function in RNA processing associated with this disease (26).
MATR3 has been involved as a modulator of ZAP activity in the restriction of retrovi-
ruses (19) and as a target for phosphorylation promoted by the alphaherpesvirus
US3/ORF66 kinases (27). Perhaps the best-studied role for MATR3 in a virus life cycle is
during HIV-1 infection. MATR3 was shown to act as a Rev cofactor and to promote the
accumulation of HIV-1 unspliced and partially spliced transcripts in the cytoplasm (15,
FIG 7 Rescue of MATR3 from J-lat-depleted cells shows dependence for HIV-1 release. (A) Design of a
mutant MATR3 (f-MATR3R) resistant to shMATR3 depletion. The target sequence of shMATR3_905 was
mutated in 3 positions without changing the amino acid composition of the protein. Inserted mutations
were T552C (F147), A555G (R148), and A558G (R149). (B) Depleted endogenous MATR3 is rescued by
ectopic f-MATR3R. J-lat 6.3 cells were transduced with shMATR3_905. Three days after puromycin
selection (1 g/ml), MATR3-depleted cells were transduced either with f-MATR3 or with the mutant
f-MATR3R, which is the only one able to rescue MATR3 protein levels. Following incubation for 3 days in
blasticidin (10 g/ml), cells were processed for immune staining. (C) MATR3 is required for SAHA
reactivation from latency in the J-lat model. J-lat 6.3 cells were left untreated or transduced as above (B)
and then treated with SAHA at the concentrations indicated for 24 h. Extracellular p24 in the supernatant
was quantified by HIV-1 p24 ELISA. Results from three independent experiments are shown as mean
values  SD. (D) Depleted endogenous MATR3 is rescued by ectopic f-MATR3R. J-lat 8.4 cells were
transduced with shMATR3_905. Three days after puromycin selection, MATR3-depleted cells were
transduced with f-MATR3R. Following incubation for 3 days, cells were processed for immune staining. (E)
MATR3 is required for SAHA reactivation from latency in the J-lat model. J-lat 8.4 cells were transduced
as above (D) and then treated with SAHA for 24 h. Extracellular p24 in the supernatant was quantified
by HIV-1 p24 ELISA. Average results from two independent experiments are shown.
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16). We also proposed that PSF commits nascent HIV pre-mRNA to MATR3 in the
insoluble, nuclear-matrix-containing fraction of the nucleus. This pathway of RRE-
containing viral RNA maintenance is targeted by the Rev protein. Rev binds the nascent
viral pre-mRNA to redirect it to nuclear export through a still poorly characterized
mechanism that also involves MATR3 (18, 28). However, despite the definition of the
role of MATR3 in the nuclear export of viral RNA, we didn’t have an understanding of
the physiological role of MATR3 during viral replication and reactivation from latency.
Therefore, in this work we wished to establish the role of MATR3 in acute HIV-1
infection of CD4 T lymphocytes and in reactivation from latency following LRA
treatment in HIV aviremic patients’ cells. First, we defined an experimental setup to
modulate MATR3 levels efficiently in Jurkat cells and primary lymphocytes. Then, we
demonstrated that HIV replication was significantly reduced when MATR3 was de-
pleted, while it was enhanced when MATR3 was overexpressed. We could confirm that
MATR3 acted posttranscriptionally, at the level of nuclear export of RRE-containing
transcripts during acute infection of lymphocytes.
We then turned to study the effect of MATR3 modulation in a classical model of HIV
latency based on Jurkat cells carrying an integrated provirus. J-lat cells had reduced
levels of Gag expression when depleted of MATR3, despite full transcriptional reacti-
vation following TNF- stimulation. Intriguingly, quiescent PBLs showed low levels of
MATR3 and PSF expression, which could be readily increased by stimulation with a
potent lectin like PHA. Well-known LRAs such as SAHA, disulfiram, romidepsin, or
IngenolBJQ1 were unable to induce MATR3 levels from quiescent PBLs. Furthermore,
ex vivo cell cultures of CD8-depleted PBMCs from seven HIV patients under cART
showed low levels of MATR3 and PSF that could be stimulated by anti-CD3 and
anti-CD28 antibodies, but not by LRA treatments. Indeed, in this ex vivo model, LRAs
such as SAHA (Vorinostat) were able to activate viral transcription but failed to fully
express HIV-1. Thus, it is very likely that there might be a scenario in which reactivation
by LRAs could be restricted because of limiting levels of MATR3 and PSF, as well as
other cellular factors.
These data are consistent with the reports by other investigators showing that
certain LRAs, notwithstanding robust induction of viral transcription, failed to effec-
tively enhance virus production (29–31). These observations strongly suggest the
importance of posttranscriptional blocks as one additional mechanism leading to HIV
latency that needs to be relieved in order to purge the viral reservoir. Recent reports are
highlighting this long-overlooked aspect of HIV reactivation from latency. Indeed, HIV
latency could be redefined to include cells in the reservoir with a silent provirus, but
also cells with a transcriptionally competent virus that are unable to fully process and
translate viral RNAs. Since only fully replicating HIV is responsible for virus rebound, but
also required for purging the reservoir by the immune system in any “shock and kill”
approach, new tools are required to measure the reservoir accordingly (32, 33).
Although we were able to show direct evidence of the role of MATR3 in the
posttranscriptional regulation of HIV-1 latency in the J-lat model, it would be important
to investigate its role in primary lymphocytes. Several cellular models have been
proposed to recapitulate HIV latency in primary lymphocytes in vitro (34, 35). Most of
them include a step of T cell activation before infection and genes such as those coding
for MATR3 and PSF could remain expressed at sublimiting levels also when the HIV-1
provirus returns to the silent state. This could be directly observed from the analysis of
expressed genes in the well-described model of HIV latency in CD4 T cells developed
by the Karn laboratory, which can be queried from the open access interactive web
resource of the Telenti laboratory at http://litchi.labtelenti.org (30, 36). Alternative
strategies include the establishment of HIV latency by direct infection of resting T cells
(37, 38). However, we were not successful in modulating MATR3 levels following
protocols that increase quiescent T cell permissivity by treatment with virus-like
particles containing Vpx to degrade the restriction factor SAMHD1 (39, 40). Notwith-
standing technical difficulties, posttranscriptional regulation of HIV latency could still be
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a multifactorial process targeting steps of transcription, RNA processing, nuclear export,
and translation, therefore requiring modulation of more than one factor at a time (8).
We conclude that cellular factors such as MATR3 and PSF are poorly stimulated by
LRA treatment ex vivo in HIV-1-infected patients’ cells and that this could contribute to
poor performance of those LRAs. These data reinforce the need to further investigate
the pathways to full virus reactivation to potentiate combination LRA treatments,
including posttranscriptional targets.
MATERIALS AND METHODS
Cells. Human embryonic kidney T cells (TaKaRa Bio USA no. 632273) were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS) and antibiotics. Jurkat
and J-lat 8.4 cells were obtained from the NIH Research and Reference Reagent Program and were
maintained in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal calf serum,
penicillin, streptomycin, and L-glutamine.
The buffy coat from healthy donors was diluted to twice its volume with RPMI, layered onto
Ficoll-Hypaque, and gently centrifuged for 2,200 rpm for 30 min. PBMCs were then collected and grown
in RPMI supplemented with 10% heat-inactivated FBS and antibiotics. Nonadherent peripheral blood
lymphocytes (PBLs) were collected next day, stimulated with 10% RPMI containing 5 g/ml phytohe-
magglutinin (PHA) for 72 h, and subsequently maintained with 10% RPMI containing 20 U/ml
interleukin-2 (IL-2). Primary CD4 lymphocytes were purified from PBMCs with the Miltenyi CD4
MicroBeads by direct magnetic labeling and stimulated with PHA/IL-2 as above.
CD8-depleted PBMCs used in reactivation assays were isolated from fresh whole blood of HIV
patients on cART as previously described (41, 42). For each treatment, six million CD8-depleted PBMCs
were seeded in LGM-3 growth medium (Lonza). One day after isolation, cells were mock treated or
treated with anti-CD3 and anti-CD28 antibodies as a positive control or by LRAs for 3 and 6 days. Medium
was harvested at day 3 and replaced with fresh medium containing LRA when appropriate.
Antibodies for immunoblotting and chemicals. The following antibodies have been used in the
study: MATR3 (A300-590A, Bethyl Laboratories, 1:2,000 dilution for IB), HIV-1 p55 and p24 (HIV-1 p24
[1941], sc-65462, Santa Cruz, or anti-HIV-1 p55 p24 p17 antibody ab63917, Abcam, 1:200). Hsp90
(catalogue number ALX-804-808, Enzo Life Sciences), PARP (catalogue number ALX-210-302, Enzo Life
Sciences), -actin HRP (Sigma, AC-15, 1:10,000), PSF (B92 Sigma P2860, 1:1,000), cyclin T1 (C-20-SC-8128,
1:200), polypyrimidine tract binding protein PTB (rabbit polyclonal produced in-house, 1:1,000), flag tag
(Sigma, 1:5,000), and vimentin (Cell Signaling, 1:1,000).
Other reagents included Histopaque-1077 (10771, Sigma), Polybrene (Sigma-H9268), phytohemag-
glutinin (PHA L1668-5MG, Sigma), interleukin-2 (H7041, Sigma), TNF- (T0157, Sigma), puromycin
(ant-pr-1, InvivoGen), blasticidin (ant-bl-1, InvivoGen), SAHA (SML0061, Sigma), disulfiram (D2950000,
Sigma), romidepsin (S3020, Selleckchem), and JQ1 (2091-1, BioVision). IngenolB was kindly donated by
Luiz F. Pianowski, Kyolab/Amazônia Fitomedica-mentos, Valinhos, Sao Paulo, Brazil. Human CD3
(IMI1304) and CD28 (IMI1376) antibodies were obtained from Analis (Belgium).
Lentivectors. pLKO.1 lentiviral vectors harboring short hairpin RNA (shRNA) targeting MATR3 were
obtained from Open Biosystems (TRCN0000074903-904-905-906-907). The pLKO.1 vector plasmid ex-
pressing scrambled shRNA (obtained from Open Biosystems) was used as control (shCTRL). Ectopic
expression of MATR3 was obtained by cloning a flag-tagged MATR3 (f-MATR3) cDNA into the pWPI
lentivector (kind gift from Gualtiero Alvisi, University of Padua, Italy). The construct was modified by
site-directed mutagenesis introducing 3 silent mutations in the target region of sh905 to make it
resistance to RNAi-mediated depletion (f-MATR3R; Fig. 7A has details).
Vesicular stomatitis virus glycoprotein G (VSV-G)-pseudotyped lentiviral particles (LVPs) were pro-
duced in HEK 293 T cells by cotransfecting the vector plasmids with the HIV packaging plasmid (psPAX2)
and the VSV-G expression (pMD2G) plasmids (Addgene). The medium was replaced 16 h after calcium-
phosphate transfection. The lentiviral vector-containing supernatants were collected 48 and 72 h
posttransfection, clarified, filtered through 0.45-m syringes, aliquoted, and further stored at 80°C until
further usage.
Transduction of LVPs was obtained in the presence of 10 g/ml Polybrene. The medium was replaced
after 16 h to remove unbound virus particles. At 24 h postransduction the cells were cultured with fresh
10% RPMI containing 1 g/ml puromycin (pLKO.1 LVPs) or 10 g/ml blasticidin (pWPI LVPs).
HIV-1. Infectious HIV-1 stocks were generated by transfecting the full-length HIV-1 pNL-4.3 plasmid
into HEK-293T cells using the standard calcium phosphate transfection method. HIV-1-containing
supernatants were collected 48 and 72 h posttransfection, clarified, filtered through 0.45-m filters,
aliquoted, and further stored at 80°C until further usage. Viral production was quantified in the
supernatants for HIV-1 p24 antigen content using the Innotest HIV antigen MAb kit (Innogenetics N.V.,
Ghent, Belgium).
Jurkat cells or stimulated PBLs were infected with HIV-1 pNL-4.3 virus in the presence of 10 g/ml of
Polybrene. After 4 h of incubation, cells were washed twice and then cultured in complete RPMI medium
supplemented with IL-2.
Luciferase assay. Jurkat cells were infected with 1 g/ml of HIV-1 pNL4.3R-E-luc pseudotyped with
VSV-G envelope for 4 h. The infected cells were washed twice and further incubated at 37°C for 48 h. At
48 h postinfection, the cells were harvested and lysed in passive lysis buffer and the levels of luciferase
activity were measured by the single-luciferase-reporter assay (p.j.k.) as directed by the manufacturer. For
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normalization, total protein concentration in each extract was determined with a Bio-Rad protein assay
kit.
Nuclear and cytoplasmic fractions. Nuclear and cytoplasmic fractions were obtained essentially as
described previously (15, 18). The cytoplasmic fraction and nuclei were subjected to RNA extraction using
UPzol according to the manufacturer’s protocol (Biotechrabbit). Purity of fractions was assayed by
Western blot of cytoplasmic and nuclear proteins.
For quantitative real-time PCR (qRT-PCR), RNA was treated with DNase I (Invitrogen) to remove
genomic DNA contamination and used as a template to synthesize cDNA using random hexamers and
MMLV reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. Real-time PCR ampli-
fication was conducted in the presence of KAPA SYBR FAST Bio-Rad ReadyMix (KAPA Biosystems) and
monitored on a C1000 Thermal Cycler (Bio-Rad). The viral RNA abundance was calculated relative to the
GAPDH mRNA expression and shown as fold change in comparison with control samples. Results were
expressed as mean plus or minus standard deviations.
Study subjects. Seven HIV-1-infected individuals were selected at the St-Pierre Hospital (Brussels,
Belgium) on the basis of the following criteria: all volunteers were treated with cART for at least 1 year,
had an undetectable plasma HIV-1 RNA level (20 copies/ml) for at least 1 year, and had a level of CD4
T lymphocytes higher than 300 cells/mm3 of blood. Characteristics (age, CD4 T cell count, CD4 nadir,
antiviral regimens) of patients from the St- Pierre Hospital were well documented and are presented in
Table 1.
Ethics statement. Ethical approval for HIV-1 patients’ cells was granted by the Human Subject Ethics
Committees of the Saint-Pierre Hospital (Brussels, Belgium). All individuals enrolled in the study provided
written informed consent for donating blood. Uninfected peripheral blood mononuclear cells (PBMCs)
were obtained from healthy blood donors after approval by the Ethical Committee of the Azienda
Ospedaliero—Universitaria Ospedali Riuniti di Trieste, Italy.
Quantification of total HIV-1 DNA. The total cellular DNA was extracted from patient CD8-
depleted PBMC ex vivo cultures using the QIAamp DNA minikit. The total cell-associated HIV-1 DNA was
then quantified by ultrasensitive real-time PCR (Generic HIV DNA cell kit, Biocentric) according to the
manufacturer’s instructions (43).
Quantification of cell-free HIV-1 RNA in culture supernatants of patient cells. Three and 6 days
after treatment with LRAs, culture supernatants from patient CD8-depleted PBMC ex vivo cultures were
collected for RNA extraction using the QIAamp Viral RNA minikit (Qiagen). HIV-1 RNA levels were
quantified using the Generic HIV Charge Virale kit (Biocentric) according to the manufacturer’s instruc-
tions (detection limits of 110 HIV-1 RNA copies/ml or 300 HIV-1 RNA copies/ml depending on tested
supernatant volumes).
Quantification of cell-associated HIV-1 RNA, MATR3, and PSF mRNA. Total RNA was isolated from
the patient CD8-depleted PBMCs using the Boom isolation method (44), treated with DNase (DNA-free
kit; Ambion) to remove DNA that could interfere with the quantitation, and reverse transcribed using
random primers and SuperScript III reverse transcriptase (all from Invitrogen). Cell-associated HIV RNA
was quantified using a qPCR assay specific for the HIV gag region (45). The amounts of HIV-1 RNA were
normalized to total cellular inputs, which were quantified in separate qPCR assays, using the detection
kit for 18S rRNA (Applied Biosystems, Foster City, CA), and were expressed as the number of copies per
microgram of total RNA. MATR3 and PSF mRNAs were quantified using the same cDNA preparations and
normalized to 18S rRNA. MATR3 mRNA was quantified by a qPCR assay using primers MATR3 fw_1431
(5= TCT TGG GGG ACC AGC AGT TGG A 3=) and MATR3 rev_1530 (5= GCT AGT TTC CAC TCT GCC TTT CTG
C 3=). PSF mRNA was quantified by a qPCR assay using primers PSF fw_1359 (5= AGC AGC AAG AAA GGC
ATT TGA ACG 3=) and PSF rev_1434 (5= CAC ATT GAC TGG ACG AGG AGT TG 3=).
Statistics. Typically, three independent experiments in triplicate repeats were conducted for each
condition examined. Average values are shown with standard deviation and P values, measured with a
Student t test. Only significant P values are indicated by the asterisks above the graphs (P  0.01  highly
significant [**]; P  0.05  significant [*]). Data from patients were analyzed using paired, nonparametric
Wilcoxon test or Student’s t test, as detailed in figure legends (P  0.05  significant). All tests were
two-sided.
TABLE 1 Presentation of patient characteristicsa
Patient Code
Total HIV-1 DNA
copies/106 cells Age (yr)
CD4 T
cell count Nadir Last treatments
P1 431 94 41 433 433 STB
P2 403 1,329 46 807 331 KVX RTV ATV
P3 425 184 57 359 10 3TC RTV DRV RLT ETV MVC
P4 421 317 47 16 16 KVX RTV DRV
P5 410 553 56 789 321 TRU ATV
P6 408 1,627 58 NA 25 TRU RTV DRV
P7 15 1,442 59 1,083 92 RTV DRV ETV MVC
aCharacteristics (age, CD4 T cell count, CD4 nadir, antiviral regimens) and total HIV-1 DNA copies/million
of CD8-depleted PBMCs of patients from the St-Pierre Hospital are presented. NA, not available.
Abbreviations: STB, elvitegravir/cobicistat/emtricitabine/tenofovir DF; KVX, Kivexa; RTV, ritonavir; ATV,
atazanavir; 3TC, lamivudine; DRV, darunavir; RLT, raltegravir; ETV, etravirine; MVC, maraviroc; TRU, Truvada;
ETV, etravirine.
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